BIOVF Company Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.

In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus.

The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Swedish Orphan Biovitrum AB (publ)

Country	Sweden
Founded	1939
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,772
CEO	Guido Oelkers

Contact Details

Address: TomtebodavAegen 23A Solna, 112 76 Sweden
Phone	46 86 97 20 00
Website	sobi.com

Stock Details

Ticker Symbol	BIOVF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0000872095
SIC Code	2836

Key Executives

Name	Position
Guido Oelkers	Chief Executive Officer
Henrik Stenqvist	Chief Financial Officer